Recent 8-K filings for EYPT

• May 14, 2026, 7:05 AM ET other material materiality 0.75 positive item 8.01item 9.01

  EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials

  DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.

• May 6, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026

  Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.

• April 13, 2026, 7:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  EyePoint posts updated investor presentation; no material new information disclosed

  Investor presentation posted on April 13, 2026 on company website.

• March 20, 2026, 7:59 PM ET litigation materiality 0.60 negative item 7.01

  EyePoint files defamation lawsuit against Ocular Therapeutix over false statements about DURAVYU

  Complaint filed March 20, 2026 in Middlesex County Superior Court (Massachusetts).

• March 4, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026

  Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).

• March 2, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027

  First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.

• January 7, 2026, 6:59 PM ET other material materiality 0.65 neutral item 2.02item 9.01

  EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026

  Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.

• December 8, 2025, 6:59 PM ET other materiality 0.00 neutral item 5.03item 9.01 ◈ Governance Changes

  EyePoint Pharmaceuticals renamed to EyePoint, Inc. effective Dec 8, 2025

  Corporate name changed to EyePoint, Inc.; no change to ticker symbol EYPT.

• November 19, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes

  DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.

• November 6, 2025, 6:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  EyePoint Pharmaceuticals files $200M ATM equity offering with Cantor Fitzgerald

  Registered at-the-market offering of up to $200 million of common stock under a prospectus supplement filed November 6, 2025.

• November 5, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing

  Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).

• October 17, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01

  EyePoint raises ~$150M in public offering to fund DURAVYU clinical development

  Pricing: 11M shares at $12.00 each; 1.5M pre-funded warrants at $11.999 each.

• October 14, 2025, 7:59 PM ET other material materiality 0.72 positive item 2.02item 8.01item 9.01

  EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data

  First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.

• August 6, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD

  Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.

• July 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026

  LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.

• July 29, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026

  LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.

• June 20, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  EyePoint shareholders approve 2.9M share increase to 2023 equity plan at annual meeting

  All 8 director nominees elected; say-on-pay approved with ~93% of votes cast.

• May 27, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026

  Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.

• May 7, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 8.01item 9.01

  EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA

  Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.

• March 5, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations

  Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.

• March 4, 2025, 6:59 PM ET other material materiality 0.15 neutral item 8.01item 9.01

  EyePoint posts updated investor presentation for TD Cowen conference

  Presentation dated March 4, 2025, was filed as Exhibit 99.1 and posted on company website.

• February 5, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain

  DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.

• January 13, 2025, 6:59 PM ET other material materiality 0.70 positive item 2.02item 8.01item 9.01

  EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025

  Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.

• January 8, 2025, 6:59 PM ET leadership materiality 0.40 positive item 5.02item 8.01item 9.01 ◈ executive_change

  EyePoint appoints Dr. Reginald Sanders, retina specialist and former ASRS president, to board

  Board expanded to nine members; Dr. Sanders appointed effective Jan 8, 2025.

• December 4, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026

  First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.

• November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing

  Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.

• October 31, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development

  Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.

• October 28, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01

  EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA

  DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.

• October 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026

  First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.

• September 4, 2024, 7:59 PM ET leadership materiality 0.60 positive item 5.02item 8.01item 9.01 ◈ executive_change ×3

  EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles

  David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.

• August 7, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026

  Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.

• June 26, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01

  EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data

  Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.

• June 21, 2024, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01

  EyePoint shareholders approve 4M share increase for 2023 LTIP, 250K for ESPP at annual meeting

  Approved amendment to 2023 Long-Term Incentive Plan: authorized shares increased by 4,000,000.

• May 28, 2024, 7:59 PM ET other material materiality 0.25 neutral item 8.01item 9.01

  EyePoint posts updated investor presentation; no specific financial updates in excerpt

  Filed investor presentation dated May 2024 as Exhibit 99.1 on May 28, 2024.

• May 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  EyePoint Q1 net loss $29.3M; DURAVYU Phase 2 NPDR trial misses primary endpoint; cash runway to 2026

  Q1 net loss $29.3M ($0.55/shr) vs $21.2M ($0.56/shr) in Q1 2023; revenue $11.7M (+52% YoY) from YUTIQ deferred revenue.

• May 6, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months

  Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.

• March 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD

  Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).

• March 4, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 8.01item 9.01

  EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino

  Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

18 positive 1 negative 19 neutral

source · EYPT on sec.gov